Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more
Shuttle Pharmaceuticals Inc (SHPH) - Net Assets
Latest net assets as of September 2025: $1.39 Million USD
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has net assets worth $1.39 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.54 Million) and total liabilities ($2.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.39 Million |
| % of Total Assets | 39.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2918.75 |
Shuttle Pharmaceuticals Inc - Net Assets Trend (2017–2024)
This chart illustrates how Shuttle Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shuttle Pharmaceuticals Inc (2017–2024)
The table below shows the annual net assets of Shuttle Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $709.15K | -82.51% |
| 2023-12-31 | $4.06 Million | -47.18% |
| 2022-12-31 | $7.68 Million | +571.58% |
| 2021-12-31 | $-1.63 Million | +3.68% |
| 2020-12-31 | $-1.69 Million | -6256.38% |
| 2018-12-31 | $27.46K | +109.66% |
| 2017-12-31 | $-284.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shuttle Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3329365300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $41.00 | 0.01% |
| Other Components | $35.29 Million | 4975.97% |
| Total Equity | $709.15K | 100.00% |
Shuttle Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viver Incorporadora e Construtora S.A
SA:VIVR3
|
$1.59 Million |
|
SOTHEMA
BC:SOTHEMA
|
$1.59 Million |
|
IPB Petroleum Ltd
AU:IPB
|
$1.59 Million |
|
Pacte Novation
PA:MLPAC
|
$1.59 Million |
|
Altur Slatina
RO:ALT
|
$1.58 Million |
|
Mohit Industries Limited
NSE:MOHITIND
|
$1.58 Million |
|
Visioneering Technologies Inc
AU:VTI
|
$1.58 Million |
|
HIGH QUALITY FOOD
F:L24
|
$1.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shuttle Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,055,771 to 709,152, a change of -3,346,619 (-82.5%).
- Net loss of 9,144,797 reduced equity.
- New share issuances of 3,992,675 increased equity.
- Other factors increased equity by 1,805,503.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.14 Million | -1289.54% |
| Share Issuances | $3.99 Million | +563.02% |
| Other Changes | $1.81 Million | +254.6% |
| Total Change | $- | -82.51% |
Book Value vs Market Value Analysis
This analysis compares Shuttle Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.02 | $1.00 | x |
| 2018-12-31 | $0.00 | $1.00 | x |
| 2020-12-31 | $-0.12 | $1.00 | x |
| 2021-12-31 | $-0.12 | $1.00 | x |
| 2022-12-31 | $0.74 | $1.00 | x |
| 2023-12-31 | $0.25 | $1.00 | x |
| 2024-12-31 | $0.07 | $1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shuttle Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1289.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.53x
- Recent ROE (-1289.54%) is below the historical average (-542.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-185.16K |
| 2018 | -2280.52% | 0.00% | 0.00x | 22.63x | $-628.88K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-636.70K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-989.32K |
| 2022 | -65.07% | 0.00% | 0.00x | 1.13x | $-5.76 Million |
| 2023 | -162.55% | 0.00% | 0.00x | 1.47x | $-7.00 Million |
| 2024 | -1289.54% | 0.00% | 0.00x | 3.53x | $-9.22 Million |
Industry Comparison
This section compares Shuttle Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shuttle Pharmaceuticals Inc (SHPH) | $1.39 Million | 0.00% | 1.54x | $1.58 Million |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |